ENvue Medical, Inc.
FEEDHealthcareNASDAQMedical Devices · Last scanned Sep 8, 2026
Scan Results
Daily timeframeENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration. At a $4.0M market cap, ENvue Medical, Inc. ranks as a micro-cap company within healthcare. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.
Market Cap
$4.0M
Beta
1.38
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-302.64
EPS (Fwd)
—
ROE
-59.1%
ROA
-21.0%
Cash
$1.1M
Total Debt
$1.3M
Free CF
-$5.8M
52W Change
-94.3%
Annual Financials
Cash vs Debt
Where FEED stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, FEED finished 72.71% below its 150-day moving average ($15.06) and 79.83% below its 200-day moving average ($20.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FEED overbought or oversold?
At the September 3, 2026 close, FEED's RSI(14) was 42.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $1.1M in cash, though total debt stands at $1.3M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$5.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -59.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $752K (2022) to $2.6M (2025), reflecting a 239% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing FEED's risk profile alongside its fundamentals and technical indicators provides a more complete picture.